Dyslipidemias: Pathophysiology, Evaluation and Management

ISBN-13: 9781493958528 / Angielski / Miękka / 2016 / 525 str.

Abhimanyu Garg

Opis

Dyslipidemias: Pathophysiology, Evaluation and Management provides a wealth of general and detailed guidelines for the clinical evaluation and management of lipid disorders in adults and children.

Spis treści

Chapter 1. Lipoprotein Physiology

 

Chapter 2. Epidemiology of Blood Lipids and Lipoproteins

 

Chapter 3. Lipoprotein(a)

 

Chapter 4. Lipoproteins and Cardiovascular Disease Risk

 

Chapter 5. Detection and Treatment of Children and Adolescents with Dyslipidemia

 

Chapter 6. Type 2 Diabetes Mellitus and Dyslipidemia   

 

Chapter 7. Type 1 Diabetes Mellitus and Dyslipidemia

Chapter 8. Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome

Chapter 9. Dyslipidemia in HIV-infected Patients

Chapter 10. Monogenic Hypercholesterolemia

Chapter 11. Primary Hypertriglyceridemia

Chapter 12. Genetic Disorders of HDL Metabolism

Chapter 13. Sitosterolemia and Other Rare Sterol Disorders

Chapter 14. Genetic Abetalipoproteinemia & Hypobetalipoproteinemia

Chapter 15. Drug-induced Dyslipidemia

Chapter 16. Lipodystrophies and Dyslipidemias

Chapter 17. Novel Genes for Dyslipidemias: Genome-Wide Association Studies

Chapter 18. Perspectives on Cholesterol Guidelines

Chapter 19. Nutrition and Coronary Heart Disease Prevention

Chapter 20. Phytosterol Therapy

Chapter 21. N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease

Chapter 22. Polyphenols for Cholesterol Management

Chapter 23 - Dietary Supplements for Cholesterol Management

Chapter 24. Statins: Risk-Benefits and Role in Treating Dyslipidemias

Chapter 25. Fibrates: Risk-Benefits and Role in Treating Dyslipidemias

Chapter 26. Niacin: Risk-Benefits and Role in Treating Dyslipidemias

Chapter 27. Bile Acid Sequestrants: Risk-Benefits and Role in Treating Dyslipidemias

Chapter 28. Cholesterol Absorption Inhibitor-Ezetimibe: Risk-Benefits and Role in Treating Dyslipidemias

Chapter 29. Low Density Lipoprotein (LDL) Apheresis

Chapter 30. Novel Lipid Lowering Agents

O autorze

Abhimanyu Garg, MBBS, MD

Professor of Internal Medicine

UT Southwestern Medical Center

Department of Internal Medicine

5323 Harry Hines Blvd

Dallas, TX 75390

TEL    214-648-2895

Blurb

Dyslipidemias: Pathophysiology, Evaluation and Management provides a wealth of general and detailed guidelines for the clinical evaluation and management of lipid disorders in adults and children.  Covering the full range of common through rare lipid disorders, this timely resource offers targeted, practical information for all clinicians who care for patients with dyslipidemias, including general internists, pediatric and adult endocrinologists, pediatricians, lipidologists, cardiologists, internists, and geneticists.  For the last twenty years, there has been a growing recognition worldwide of the importance of managing dyslipidemia for the primary and secondary prevention of atherosclerotic vascular disease, especially coronary heart disease. This has been mainly due to the publication of the guidelines of National Cholesterol Education Program’s Adult Treatment Panel and Pediatric Panel from the United States. These guidelines have stimulated generation of similar recommendations from all over the world, particularly Europe, Canada, Australia and Asia.  Developed by a renowned group of leading international experts, the book offers state-of-the-art chapters that are peer-reviewed and represent a comprehensive assessment of the field.  A major addition to the literature, Dyslipidemias: Pathophysiology, Evaluation and Management is a gold-standard level reference for all clinicians who are challenged to provide the best care and new opportunities for patients with dyslipidemias.